达安基因
(002030)
| 流通市值：104.84亿 | | | 总市值：104.84亿 |
| 流通股本：14.03亿 | | | 总股本：14.03亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,180,897,087.04 | 842,336,232.83 | 536,218,449.35 | 341,038,087.62 |
| 营业收入 | 1,180,897,087.04 | 842,336,232.83 | 536,218,449.35 | 341,038,087.62 |
| 利息收入 | 0 | 0 | - | - |
| 已赚保费 | 0 | 0 | - | - |
| 手续费及佣金收入 | 0 | 0 | - | - |
| 二、营业总成本 | 1,133,440,757.45 | 822,995,285.9 | 554,210,715.32 | 331,655,918.97 |
| 营业成本 | 584,929,093.72 | 380,716,762.3 | 252,528,902.45 | 150,889,525.36 |
| 利息支出 | 0 | 0 | - | - |
| 手续费及佣金支出 | 0 | 0 | - | - |
| 退保金 | 0 | 0 | - | - |
| 赔付支出净额 | 0 | 0 | - | - |
| 提取保险合同准备金净额 | 0 | 0 | - | - |
| 保单红利支出 | 0 | 0 | - | - |
| 分保费用 | 0 | 0 | - | - |
| 税金及附加 | 9,781,719.09 | 4,600,340.02 | 2,853,237.54 | 1,264,795.54 |
| 销售费用 | 172,833,278.42 | 135,653,918.48 | 102,470,794.71 | 53,169,470.42 |
| 管理费用 | 138,313,374 | 140,633,040.1 | 97,853,479.8 | 61,615,003.12 |
| 研发费用 | 302,332,171.04 | 222,724,481.01 | 151,908,136.77 | 76,407,740.73 |
| 财务费用 | -74,748,878.82 | -61,333,256.01 | -53,403,835.95 | -11,690,616.19 |
| 其中:利息费用 | 10,042,125.86 | 5,106,898.21 | 2,809,252.37 | 1,191,644.09 |
| 其中:利息收入 | 83,099,536.1 | 61,771,253.01 | 45,564,878.07 | 20,616,223.95 |
| 加:公允价值变动收益 | 435,690,646.25 | 403,291,564.96 | 479,960,170.65 | 23,574,185.76 |
| 加:投资收益 | -26,246,655.88 | -334,952.78 | 20,089,978.44 | -13,106,754.85 |
| 净敞口套期收益 | 0 | 0 | - | - |
| 汇兑收益 | 0 | 0 | - | - |
| 资产处置收益 | -3,039,675.21 | -110,841.37 | 0 | - |
| 资产减值损失(新) | -262,753,953.87 | -24,413,320.63 | -15,050,080.38 | - |
| 信用减值损失(新) | -153,689,485.16 | -44,191,268.59 | -682,891.61 | 13,206,106.57 |
| 其他收益 | 84,204,656.3 | 77,951,811.63 | 22,775,318.86 | 17,467,342.87 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 121,621,862.02 | 431,533,940.15 | 489,100,229.99 | 50,523,049 |
| 加:营业外收入 | 1,889,579.2 | 1,534,885.17 | 1,493,868.76 | 57,193.02 |
| 减:营业外支出 | 9,975,491.46 | 3,485,967.15 | 3,282,090.18 | 655,060.36 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 113,535,949.76 | 429,582,858.17 | 487,312,008.57 | 49,925,181.66 |
| 减:所得税费用 | 41,804,363.65 | 83,479,779.01 | 88,919,291.85 | 12,147,268.96 |
| 六、净利润 | 71,731,586.11 | 346,103,079.16 | 398,392,716.72 | 37,777,912.7 |
| 持续经营净利润 | 71,731,586.11 | 346,103,079.16 | 398,392,716.72 | 37,777,912.7 |
| 终止经营净利润 | 0 | 0 | - | - |
| 归属于母公司股东的净利润 | 104,659,624.06 | 352,594,428.71 | 402,755,388.71 | 36,561,352.66 |
| 少数股东损益 | -32,928,037.95 | -6,491,349.55 | -4,362,671.99 | 1,216,560.04 |
| (一)基本每股收益 | 0.07 | 0.25 | 0.29 | 0.03 |
| (二)稀释每股收益 | 0.07 | 0.25 | 0.29 | 0.03 |
| 八、其他综合收益 | -867,076.31 | 423,297.85 | 400,942.9 | -369,592.19 |
| 归属于母公司股东的其他综合收益 | -1,067,187.13 | 248,466.26 | 192,555.76 | -258,428.99 |
| 九、综合收益总额 | 70,864,509.8 | 346,526,377.01 | 398,793,659.62 | 37,408,320.51 |
| 归属于母公司股东的综合收益总额 | 103,592,436.93 | 352,842,894.97 | 402,947,944.47 | 36,302,923.67 |
| 归属于少数股东的综合收益总额 | -32,727,927.13 | -6,316,517.96 | -4,154,284.85 | 1,105,396.84 |
| 公告日期 | 2024-03-30 | 2023-10-31 | 2023-08-31 | 2023-04-29 |
| 审计意见(境内) | 标准无保留意见 | | | |